This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Avita Medical, Inc.
11/5/2026
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Avita Medical, Inc., third quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question at that time, you will need to press star 1-1 on your telephone keypad. As a reminder, this conference call is being recorded. At this time, I would like to turn the call over to Mr. Ben Atkins, Vice President of Investor Relations. Sir, please begin.
Thank you, operator. Welcome to Avita Medical's third quarter 2026 earnings call. Joining me on today's call are Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website at www.avitamedical.com under the Investor Relations section. Before we begin, I would like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties that could cause actual results to differ materially from any expectations expressed or implied by the forward-looking statements. Please review our most recent filings with the SEC for comprehensive descriptions of the risk factors. Any forward-looking statements provided during this call are based on management expectations as of today. I will now turn the call over to Cary. Good afternoon in the US and good morning in Australia. As always, we appreciate you making the time to join us on our quarterly update call. Before I discuss the quarter, I want to acknowledge the clinicians caring for patients with serious burn injuries following the devastating fire at the Wainwright Military Base in Alberta, Canada. At their request, we mobilized quickly We donated about three dozen resell units to burn centers in Calgary and Edmonton and sent a lead of staff to train and to support the clinical teams. Within days, the first patient received treatment with resell. Serious burn injuries can happen without warning. Responding takes preparation, access to treatment, and people ready to act. I want to thank our team. the clinicians and burn community in Canada, and the American Burn Association for connecting us. Resell is not commercially available in Canada, and we are grateful to Health Canada for acting quickly to facilitate access. This response brings us back to why we do this work, helping people heal from serious wounds and return to their lives. Let me turn to our third quarter performance. Revenue reached $26.1 million. up 53% year-over-year and 20% from the second quarter. Resell led that growth, supported by increasing adoption of CoHelix. We'll further discuss our product dynamics in a moment. At the same time, we reduced cash use to approximately $600,000, compared with $3.2 million in Q2. We are growing revenue. but we're also managing expenses and cash diligently. That combination continues to improve the financial position of the company. Based on our performance, we are raising full year revenue guidance for the second consecutive quarter. We now expect revenue of $92 to $94 million for the full year compared with our previous range of $86 to $89 million. We also remain on track to achieve cash flow breakeven in the fourth quarter. David will walk through the financial results and our liquidity in more detail. First, I want to put our progress in context. A year ago, our priorities were to stabilize resale utilization, rebuild engagement with our core accounts, and improve how we operate. In Q1, we began to see those actions translate into more consistent demand. In Q2, that demand supported further growth. and gave us the confidence to raise guidance and establish our cash flow break even goal. Q3 builds on that progress. We continue to grow within our accounts. Hospitals are ordering more resale. Cohelix is reaching additional customers and revenue growth is translating into lower cash use. Our commercial approach remains focused. We target high volume burn and level one trauma centers were clinicians treat burns, traumatic injuries, and complex surgical wounds. We estimate this focused US addressable market at approximately $1.3 billion annually. Our task is to grow within that market by supporting more physicians, more eligible procedures, and broader use of our portfolio within each account. Let me start with resale. US resale revenue reached $22.4 million, approximately 20% above Q2. US resale volume increased to 3,196 units, up approximately 21% sequentially. That's always an increase of more than 11% in Q2 over Q1. The growth reflects higher procedure volumes and increased ordering across our accounts. Riso Go and Riso Go Mini give clinicians options for treating different sized wounds. Mini extends the platform into smaller wounds, while Riso Go supports treatment of larger areas. That matters because the opportunity within a hospital extends across different patients, wound sizes, and surgical teams. Our commercial and clinical teams work with physicians to identify appropriate cases provide training and support consistent use. As physicians gain experience, they can assess where resale fits within their practice. The clinical evidence supporting that work also continues to grow. In October, the Journal of Plastic, Reconstructive, and Aesthetic Surgery published a systematic review that examined 99 studies across 13 countries, covering more than two decades of experience. with skin cell suspension autographing, essentially resell. All six comparative studies that assessed donor skin requirements reported reductions with our technology, while the 18 studies evaluating healing reported either favorable or comparable outcomes. The studies varied in design and quality, but together they document a broad base of clinical experience across burns and other wound types. For clinicians, reducing the amount of donor skin matters. A donor site creates another wound that then needs to heal. Reducing that burden can make a meaningful difference to a patient's recovery. Burn care established resales clinical foundation and remains an important source of growth. We also see opportunity in trauma and surgical repair where physicians face many of the same challenges in achieving wound closure and healing. As we discussed last quarter, a new Category 1 CPT code family for skin cell suspension autographing is scheduled to take effect on January 1, 2027. It will simplify the current structure from eight codes to four based on wound size and anatomic location. This week, the Centers for Medicare and Medicaid Services, or CMS, issued its final rule and established national Relative Value Units for physicians performing procedures using resale under the Medicare Physician Fee Schedule. Once effective in January, the new framework will replace today's region-by-region Medicare Administrative Contractor Pricing with nationally published RVUs. Clinicians have shared encouraging feedback about the simpler structure. Our team is ready to support hospitals with coding information and practical implementation guidance. International resale revenue was approximately $900,000, essentially flat with Q2. We continue to build experience with ResaleGo in markets where we have regulatory authorization, including the first ResaleGo cases in Australia, where resale was originally developed by Dr. Wood. While international remains a smaller contributor today, Our focus on training, clinical experience, and local relationships in key markets continues to support steadily broadening adoption over time. Let me turn to CoHelix. Revenue reached $2.1 million, up approximately 21% from Q2. We continue to add customers as hospitals complete their value analysis committee reviews and begin using CoHelix. Those reviews are an important part of adoption. Hospitalists need to assess the clinical evidence, understand the economics, and determine how a product fits into their treatment protocols. The interim COHELIX-1 results support those discussions. The study reported a median time to graft readiness of approximately 11 days, with some patients ready within the first week. We expect a complete six-month follow-up data set this month. That will add information on longer-term outcomes to the early evidence we have already shared. Our focus remains on helping hospitals complete their evaluations and supporting clinicians as they gain experience with the product. Turning to Permiderm, revenue was approximately $600,000, essentially flat with Q2. At this early stage, the timing of individual orders can affect quarterly comparisons. We are focused on building a broader base of regular use. The Permioderm-1 results we reported in August give us stronger evidence to support that work. This randomized study enrolled 40 patients across 11 U.S. burn centers. It compared Permioderm with Allograft, which is human skin transplanted from a deceased donor for temporary wound coverage before definitive split thickness skin grafting. The study met its primary endpoint. Permiaderm demonstrated a 70% economic advantage over Allograft, measured by product cost per percent total body surface area treated. It also reduced preparation time by approximately 96%, with comparable graft take and wound healing outcomes. Approximately 94% of Permioderm patients achieved at least 95% graft take one week after autographing. All patients in both groups were healed by eight weeks. These results support a clear role for Permioderm as a wound temporizer. Hospitals can store it at room temperature and use it without tissue tracking, thawing, and meshing, while maintaining comparable application time in the operating room. Its transparency allows clinicians to assess the wound without removing the covering. Those features address practical challenges in burn care, product availability, preparation time, and visibility of the wound. We have submitted the study for publication and are using the findings in clinical education and hospital evaluations. The commercial work now is to translate that evidence into adoption and repeat use. Across the portfolio, each product serves a distinct purpose. Permiderm protects and stabilizes the wound. Co-helix rebuilds the wound bed. Re-cell restores the patient's skin. That gives us several ways to meet clinical needs within the same account, based on the patient and the treatment plan. The American Burn Association's regional burn conferences provide an important forum for clinicians to share emerging evidence and practical experience. Across the four regional conferences this year, 26 presentations involve Aveda technologies. This surpasses the cumulative presence of several leading competitors. The presentations cover resale outcomes in pediatric, geriatric, and other complex burn populations. as well as applications in facial and hand reconstruction and limb salvage. Four include treatment approaches using two or more Aveda products, while others present clinical data for cohelix and permuderm. With three regional conferences now completed and one more next week, this high level of engagement highlights the growing adoption of our portfolio and further expands the evidence supporting wider clinical use. Before I hand over to David, I want to put our fourth quarter outlook in the context of the year's progress. Our full year guidance implies Q4 revenue of approximately $24.9 to $26.9 million. At the midpoint, that would deliver approximately 30% growth for the full year over 2025. Looking across the year, revenue has increased from $19.3 million in Q1 to $21.7 million in Q2, and our Q4 range reflects continued growth from that base. Q3 was particularly strong at $26.1 million and may have benefited a bit from seasonal high burn admissions during the summer. Our guidance accommodates that third quarter variability while reflecting the consistent, stronger sequential performance we have delivered through September. We remain focused on finishing the year strongly and reaching cash flow break even. Our priorities are consistent. Expand resale utilization, grow adoption of Cohelix and Permuter, and maintain commercial growth and financial discipline. With that, I'll hand it over to David.
Thank you, Cary. Good afternoon, and in Australia, good morning. Our third quarter result illustrates how sustained revenue growth is dramatically improving the financial performance of our business. We increased revenue by 20% from the second quarter, expanded gross margin to 84%, and held operating expenses flat. Together, those results decreased quarterly cash use to approximately $600,000 from $3.2 million in Q2. We also reached the revenue milestone required to draw down the remaining $10 million under our credit facility with Perceptive Advisors, LLC. We received those funds this week, strengthening our cash reserves as we approach cash flow breakeven. In my prepared remarks that follow, I will walk through the financial results for the quarter, our liquidity, and our updated outlook. Starting with revenue, third quarter revenue was $26.1 million, an increase of 53% from $17.1 million in the same period last year, and 20% from the second quarter of this year. That brings revenue for the first nine months of 2026 to approximately $67.1 million. As Cary outlined, resale led the growth. with additional contributions from Cohelix. From a financial perspective, the important point is that we are supporting the higher revenue with essentially the same operating cost base. Total operating expenses were $24.6 million flat when compared with the second quarter and up 7% compared to $23 million in the prior year period. As we expected, the majority of the increase from last year was in sales and marketing expenses. This was largely because of commissions and incentive compensation associated with stronger commercial performance. As I have discussed, sales compensation, specifically commissions, will increase as our commercial team delivers more revenue. We carefully manage the rest of the cost base so that revenue growth translates into better bottom line financial results. That is what we saw this quarter. Compared with Q2 of this year, revenue increased by approximately $4.4 million with no increase in operating expense. We continue to review spending across the business and identify opportunities to improve efficiency while supporting our commercial priorities. Turning to gross margin, gross margin increased to 84%, a 270 basis point increase compared with 81.3% in the prior year quarter and 81.9% in the second quarter. Higher resale revenue and improvements in manufacturing efficiency contributed to that increase. Resale gross margin reached 88.4% and we currently expect it to remain between 85% and 90% over the coming quarters. As I have discussed previously, CoHelix and Permiaderm carry lower gross margins than Resell. As revenue from these products increase, they ultimately will affect our overall gross margin percentage. However, we still see significant opportunity for growth in Resell revenue So the decrease in margin should not be substantial. Our other two products will contribute additional gross profit without requiring a proportional increase in operating expenses. That remains an important part of the financial value of our portfolio. For the third quarter, we generated approximately $21.9 million in gross profit. An increase of approximately $4.2 million from the second quarter of this year. Net loss improved to $6.2 million, or a loss of $0.20 per share, compared with $13.2 million, or a loss of $0.46 per share in the same period last year. The current quarter net loss included approximately $2.1 million in non-cash expense related to the revaluation of warrants. as our share price increased. That expense negatively impacted net loss and loss per share, but again, was non-cash. Now turning to cash. On our Q2 call, we said we expected a further reduction in cash use during the third quarter. We over-delivered on that metric as we approached cash generation. Net cash use declined to approximately 600,000 compared with 3.2 million in Q2 and 9.9 million in Q1. We ended September with approximately 10.5 million in cash, cash equivalents and marketable securities. The improvement reflects higher revenue, strong gross margins and continued expense and working capital management. It also demonstrates the operating leverage we have been working towards as the business grows. Turning to liquidity, The perceptive credit facility we executed in January of this year provided for a $10 million second tranche of debt if we were to achieve at least $85 million in trailing 12-month net revenue. We have satisfied that revenue milestone, and this week we received the remaining $10 million under the credit facility. The additional funds strengthen our cash reserves as we move towards cash flow breakeven and cash generation and will be reflected in our 2026 year-end balance sheet. Our improved operating performance and liquidity also supported an important change in our financial reporting. Management concluded that the substantial doubt about our ability to continue as a going concern had been alleviated. Our independent auditor concurred with that assessment. Accordingly, our third quarter Form 10-Q no longer includes that substantial doubt qualification, and the outstanding debt has now been classified as a long-term liability. The Form 10-Q does include disclosures on the plan management undertook to alleviate the going concern conclusion found in previous quarters. These developments reflect the progress we have made in improving both the operating performance and financial position of the company. Turning to our outlook, we are raising full year 2026 revenue guidance to $92 million to $94 million from our previous range of $86 million to $89 million. This is our second consecutive quarterly increase in revenue guidance. The new range represents approximately 28% to 31% growth over 2025. at the midpoint of the range would be $93 million in annual revenue. That compares with approximately $35 million in 2022 and represents a compound annual growth rate of approximately 28% over four years and returning to a more attractive growth trajectory compared to 2025. We also reaffirm our expectation of achieving cash flow breakeven in the fourth quarter. We will continue to manage spending and collections carefully as we work to deliver that fourth quarter goal. The financial trends supporting that outlook remain clear. Revenue has grown each quarter this year. Gross margin has strengthened. We have maintained control of operating expenses and cash use has declined substantially. In summary, Q3 demonstrates that higher revenue is translating into better financial performance. We substantially reduced cash use, strengthened our liquidity after quarter end, and raised our full-year revenue outlook. I want to thank our teams across Aveda for the work behind those results. With that, I'll hand the call back to Cary.
You're reading a preview of the RCEL Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing